Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bamipine SCHEMBL4424873 | 0.98 | KCNH2 (0.64) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| Bamipine SCHEMBL1649707 | 0.97 | KCNH2 (0.63) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| Bamipine SCHEMBL3217102 | 0.93 | OPRM1 (0.59) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| Bamipine SCHEMBL443443 | 0.89 | KCNH2 (0.55) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| Bamipine SCHEMBL2968324 | 0.88 | KCNH2 (0.54) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3542065 | 0.87 | KCNH2 (0.56) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27703455 | 0.86 | SLC6A2 (0.54) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12730900 | 0.81 | KMT2A (0.58) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4492889 | 0.81 | OPRD1 (0.61) | OPRM1 | |
| SCHEMBL16307374 | 0.81 | POLB (0.57) | KCNH2DRD3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4683527-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-12497381-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-12-16 | — | — | US | claimed |
| US-12478091-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-11-25 | — | — | US | claimed |
| US-12358889-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-07-15 | — | — | US | claimed |
| US-12358888-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-07-15 | — | — | US | claimed |
| WO-2025096261-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025049141-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250049096-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2025-02-13 | — | — | US | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| US-20040171562-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | E. R. SQUIBB & SONS, L.L.C. | 2004-09-02 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20020151541-A1 | For treatment of respiratory tract diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| EP-0704206-B1 | Pharmaceutical composition | MIKA PHARMA GES FUER DIE ENTWI (DE) | 2002-09-04 | — | — | EP | claimed |
| WO-2002015700-A1 | PRODRUGS ACTIVATED BY PLASMIN AND THEIR USE IN CANCER CHEMOTHERAPY | COULTER PHARMACEUTICAL, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| EP-0713380-B1 | FUNCTIONAL OXYGENATED COMPOSITION CONTAINING PHOSPHOLIPIDS AND FLUOROCARBON | LANCASTER GROUP GMBH (DE) | 2001-09-05 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1994008840-A1 | MARINE ORGANISM REPELLENT FOR PROTECTING UNDERWATER OBJECTS | FISCHER KENNETH J (US) | 1994-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171562-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | PLG, PLAT, DNPEP | KCNH2 4842/4885DRD3 4090/4885SLC6A2 4542/4885 |
| US-12358888-B2 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | KCNH2 128/4885DRD3 556/4885SLC6A2 410/4885 |
| US-12358889-B2 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | KCNH2 128/4885DRD3 556/4885SLC6A2 410/4885 |
| US-12497381-B2 | Vaporizable alkaloid compositions and methods of use thereof | CHRM5, NNMT, CHRM1 | KCNH2 232/4885DRD3 532/4885SLC6A2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.